Dr. Laurent Leksell, Elekta’s Founder and Chairman of the Board, and IAEA’s Director General, Dr. Rafael Mariano Grossi meet in Stockholm to discuss reducing the global cancer burden
AushadhAI is purposefully designed to deliver significant advantages to the pharmaceutical supply chain's key constituents
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
The company achieved 100% capacity utilisation in the division. These accomplishments stand as a testament to the company's dedication and vision
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
Ensitrelvir is an oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Subscribe To Our Newsletter & Stay Updated
